Skip to content

Author

T. Brümmendorf

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial

It is suggested that RUX may induce clinically meaningful additional disease improvements in first-line therapy of PV patients with polycythemia vera in the randomized multicenter RuxoBEAT clinical trial.

Steffen Koschmieder, S. Isfort, Lino L. Teichmann et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.